CD4 and cryptococcosis: Furthermore, because chitosan deficiency inhibits C. neoformans survival in mammalian hosts (8, 11), even in immunocompromised hosts (data not shown), and chitosan is not produced by mammals, chitosan biosynthesis may be an ideal novel drug target for the treatment of cryptococcosis, in particular, in the context of AIDS patients who are CD4 T cell deficient.